Ischemic heart disease remains the leading cause of mortality and morbidity worldwide despite improved possibilities in medical care. Alongside interventional therapies, such as coronary artery bypass grafting, adjuvant tissue-engineered and cell-based treatments can provide regenerative improvement. Unfortunately, most of these advanced approaches require multiple lengthy and costly preparation stages without delivering significant clinical benefits.
Introduction
Despite preventive efforts and increasing awareness of risk factors, ischemic heart disease persistently maintains its rank as the global leading cause of mortality (1). Irreversible tissue damage and death of functional myocardium after, for example a myocardial infarction (MI), is repaired by fibrotic scar contributing to loss-of-function, tissue rigidity and development of heart failure (HF) over time (2) . Although drug therapies alleviate symptoms, they fail to restore lost myocardial tissue (3, 4) . Hope has been placed on regenerative tissueengineered and cell-based therapies that are expected to provide this missing part and either directly or indirectly instigate recovery of functional cardiac tissue.
For several decades, various cell-based therapies have been evaluated both preclinically and clinically but unfortunately, thus far, the approaches have had poor clinical translation due to high complexity, costs, lengthy preparation time, requirements for special production facilities, and sometimes frank incompatibility with clinical practice (5, 6) . To add to the complexity, several cell sources and types, including stem and progenitor cells from embryonic tissue, adult mesenchymal or cardiomyocyte-differentiated stem cells, have been investigated (7) . Many of these cell sources have been assessed in clinical trials, but none are used as a part of clinical practice (8) .
The studies conducted in the early 2000s that addressed cardiac progenitor cells, first in the rodent and then in adult human heart (9, 10) , generated considerable interest in functional regeneration of the heart. However, since the discovery of some major controversies concerning some of these studies, the concept of cardiac cell therapy has encountered ardent debates, emphasizing the need to re-evaluate the fundamental mechanisms underlying cardiac cell therapy. Nevertheless, cardiac progenitor cells have become a potential candidate for cell therapy (11, 12) , and these cells may be superior to other cell types in terms of regenerative effects (13, 14) . Although cardiac progenitor cells can be found in various locations throughout 4 heart (12, (15) (16) (17) , atrial tissues may contain the densest population (12, 18, 19) . Moreover, cells isolated from atrial appendage tissues have demonstrated therapeutic potential (20) . Our clinical AADC consortium recently demonstrated the clinical feasibility of direct intraoperative processing and epicardial transplantation of autologous atrial appendage micrografts (AAMs) (21, 22) . Analysis of results from a more extensive clinical feasibility trial evaluating this approach in a limited number of patients is expected be reported later this year (ClinicalTrials.gov identifier: NCT02672163).
The aim of this study was to investigate the functional efficacy and molecular therapeutic mechanisms of epicardial AAM patch transplantation in a murine model of MI and HF. The overview of the study is presented in Figure 1 .
Figure 1. Overview of the study protocol.
A schematic presentation of the processes carried out in the operating room and subsequently in the laboratory are illustrated. For further information, see the Detailed Materials and Methods. 1. For each AAM patch, both left and right atrial appendages were harvested from three syngeneic donor mice after placement of an atrial clip. 2 and 3.
Harvested appendages were disaggregated to atrial appendage micrografts (AAMs) with a Rigenera machine. 4. An ECM sheet (CorMatrix ® ECM™ for cardiac tissue repair) was peeled into four layers, and 1-ply sheets were cut into circles using an 8 mm diameter tissue punch. To create an AAM patch, we evenly dispersed the AAM suspension, containing tissue material from six appendages (three from both the right and left sides), onto the matrix sheet and sealed with a thin layer (10 μl volume) of fibrin tissue glue. 5. The AAM patch was subsequently fitted onto the recipient heart with the AAM-containing side facing the epicardium of the left ventricle at the site of infarction. The transplant was further fixed to the myocardium by three sutures to ensure that the patches remained in place. 6. After the 8-week follow-up, animals were sacrificed, hearts were excised, and ventricular tissue samples were collected for histology or snap frozen in liquid nitrogen. Apices were also collected for the measurement of ANP mRNA expression with qRT-PCR. 7. Thin histological sections were used for immunohistochemistry and morphometry. 8.
Cryosections of 12-µm thickness were collected from three anatomic groups (transplant/patch, subtransplant and septum) for proteomic profiling (9.). 10. Lastly, rest of the cryopreserved samples were used for selected validative qRT-PCR measurements, and paraffin embedded tissue samples for IHC-P staining. 6 
Results
Myocardial function. Left ventricular ejection fraction (LVEF) with corresponding area under the curve (AUC) analyses spanning the 8-week follow-up period are presented in the left and right panels of Figure 2A , respectively. ECHO recordings demonstrated better functional recovery in the AAM patch group than in the ECM patch and MI groups. Lower initial LVEF values in the Sham group were due to lower weight of the group's mice at the start of the experiment.
In all groups undergoing intervention, a decline in LVEF was evident during the first two weeks of the follow-up. However, in the AAM and ECM patch groups, the fall in LVEF seemed considerably smaller in magnitude than that observed in the MI group. The acute declines in LVEF at one-week time-point postoperatively in AAM patch, ECM patch and MI groups were as follows: 18.03 (from 54.49±2.93% to 36.69±2.56%), 19 .77 (from 52.15±3.10% to 32.38±2.96%) and 34.94 percent points (from 58.72±2.58% to 23.78±3.16%), respectively, with significant difference perceptible only between AAM patch and MI groups. However, since prevention of acute HF seemed evident in both patch groups, we hypothesize a considerable protective effect to occur by direct mechanical support, i.e.unloading, of the injured ventricle by the patch transplantation itself. The additional transplantation of micrografts might enhance the mechanical effect of the patch acutely, since the drop in LVEF was further reduced in the AAM patch group. In the later phase of the follow-up, a separation could be seen in the LVEF curves of the AAM and ECM patch groups, suggesting that the transplanted AAMs activated processes in the adjacent myocardium against the gradual development of chronic HF during a longer period of time. Significantly higher mean LVEF values were observed in the AAM group than in the MI group from 4 th week onward until the 7 th week of follow-up. At the end of follow-up, mean LVEF values reached 43.91±4.91% (AAM patch), 36.68±3.00% (ECM patch), 28.92±6.09% (MI) and 51.73±2.29% (Sham). The LVEF measurements over the entire follow-up period were supplemented with AUC analysis ( To provide further insights into the functional state of the left ventricle, we performed additional strain analyses during ECHO recordings. Comprehensive data from all strain analyses performed is presented in the online supplements ( Figure S1 for the strain data, and Table S1 for all ECHO data) and summary of the AUC data is shown here in Figure 2B -E. compared to level seen in the MI group (7.9±1.70). Interestingly, although there was no differences among the patch groups, the ANP expression level in the AAM patch group was higher than that in the Sham (1.0±0.27). This finding contradicted our primary ECHO results with better preservation and restoration of LVEF and other parameters in the AAM patch group. A plausible explanation for this elevated ANP mRNA expression could be that ANP was produced from the remnants of the transplanted micrografts, which we know to be atrial in origin with highly specialized capacity to produce ANP. In addition, the endocardial interstitial fibrosis was evaluated. Overall, the degree of tissue fibrosis in the endocardial surface was lower in both patch groups than in the MI group.
The subendocardial surface was taken into focus, since this subregion in the heart is the least tolerant to hypoxia, and thus, the subendocardial surface is the first region to be damaged and scarred after an ischemic insult. Evaluation of the endocardial fibrosis, with collagen subtype characterization, is presented in Figure 4 . Histological preservation of myocardium. We evaluated the preservation of myocardial tissue with anti-cardiac troponin T (cTnT) immunohistochemistry ( Figure 5A Subsequently, the amount of nonfibrous tissue inside the infarction scar and transplant/patch was analyzed. Figure 5C shows the quantity of tissue nodules within the site of infarction. Only tissues that did not stain with Picrosirius Red were measured. Significantly more nodules were found in the AAM patch group than in both the ECM patch and MI groups, suggesting a preservation of transplanted AAMs. The mean counts of noncollagenous tissue nodules were 3.6±0.71 (AAM patch), 0.7±0.28 (ECM patch) and 1.1±0.24 (MI). The nodules observed in the AAM patch group were also the largest, and this difference was significant compared to those in the ECM patch and MI groups ( Figure 5D ). The mean Picrosirius Rednegative tissue area encompassed 1205±258 pixels (AAM patch), 141±49 pixels (ECM patch), and 258±75 pixels (MI). However, after subsequent analyses for cTnT staining, these nodules remained cTnT negative ( Figure 5B ), suggesting that transplanted AAMs do not contribute Figure 6B ), while those related to
Cell survival and cell viability were upregulated (+3.09 and +3.36, respectively; Figure 6B ). Figure 7 and Data File S1). Together, these changes provide a molecular-level insight into the observed functional improvements.
Septal zone-Similar to the subtransplant area, Actin cytoskeleton signaling and RhoA signaling was predicted to be activated. Glutathione redox reactions I, with increased expression levels of GPX3 and GSTM2 enzymes, was also demonstrated to be significantly altered ( Figure 6A , Data File S1). Functions related to more diffuse prosurvival effects in remote septum seemed increased at the cellular, organ, and whole-organism levels in the AAM patch-treated group. At the cellular level, Cell viability was predicted to be activated (z-score +2.546), while Cell death and Apoptosis were decreased (z-scores -2.241 and -2.685, respectively, Figure 6B ). At the system level, the functions Morbidity and mortality and 22 Organismal death were predicted to be decreased (z-scores -2.481 and -2.793, respectively, Figure 6B ). Notably, overexpression of both matricellular protein POSTN (1.852-fold) and
TGM2 enzyme (1.996-fold) were also detected following AAM transplantation, far away from the initial AAM patch transplantation site (Figure 7) .
While selected canonical pathways are presented in Figure 6 , all associated canonical pathways as well as biological functions and disease states are presented in Figures S3 and S4, respectively. Selected biological functions and disease states are shown in Figure 7 from septal and subtransplant sites with associated DEPs and their expression level ratios calculated against the expression levels in ECM patch-treated controls. Table S2 further presents all DEPs with each associated canonical pathway, biological function and disease state presented in Figure 6 . Cell-based therapies and tissue engineering have long been investigated for their ability to deliver tissue regenerative adjuvant support. Atrial appendages were identified as niches for cardiac stem and progenitor cells and serve as a good autologous source of myocardial tissue for therapy due to their easy accessibility and relative redundancy for cardiac function (18, 19) .
Atrial appendage tissue is often removed and discarded during cardiac surgery to prevent formation of thrombi and predisposing the patient to thromboemboli.
In our approach, atrial appendage tissue was mechanically disaggregated after harvesting to yield micrografts (25) . An AAM patch was generated by combining the micrografts in a small amount of fibrin with a tissue-engineered ECM patch that was epicardially transplanted onto the ischemic myocardium. We recently reported a successful clinical application of the AAM patch during coronary artery bypass graft surgery (21, 22) . Here, we compared the effects of micrograft-containing AAM patches to those of corresponding acellular ECM patches in a mouse model of ischemic HF. Our results demonstrated myocardial tissue protection, attenuated scarring, and retained cardiac function after epicardial transplantation of AAM patches. These effects were associated with micrograft persistence within the transplant, suggesting that these cellular beacons emit therapeutic signals in a paracrine manner to the myocardium, a recent and emerging new hypothesis for cellular adjuvant therapies for cardiac regeneration (26, 27) .
We utilized mass-spectrometry-based quantitative proteomics to decipher those myocardial responses specific to AAMs by comparing tissue responses to matrix-patch transplants with or without AAMs after MI. We performed myocardial site-specific collection of samples from transplants, as well as from subtransplant and remote septal myocardium. Our results demonstrate a widespread cardioprotective effect on the tissue site under the transplant that also reached remote myocardial tissues. We discovered significantly decreased oxidative metabolism and oxidative stress and increased glutathione metabolism in the subtransplant area. These changes suggest an AAM-induced change in myocardial metabolism towards glycolysis, a process associated with an increased regenerative capacity of mouse myocardium in multiple studies (28) (29) (30) (31) (32) . Thus, we propose that transplanted atrial micrografts induced, likely through a paracrine mechanism, a metabolic shift from oxidative to glycolytic metabolism in the ischemically challenged subtransplant area and a pro-reparative microenvironment for surviving cardiomyocytes, ultimately setting the stage for functional recovery. This effect is further supported by our observation that functions such as "Formation of muscle" and "Differentiation of muscle cells" were activated. Moreover, restoration of functional myocardial tissue is not merely a process of cardiomyocytes, but necessitates formation of new ECM, blood vessels, and lymphatics, which are mostly orchestrated by cell types other than cardiomyocytes. Our findings demonstrate increased angiogenesis, vasculogenesis, and widespread prosurvival changes in the myocardium, which indicate induction of a protective and restorative myocardial environment by AAMs. Interestingly, our results from proteomics showed significantly increased expression levels of the cardiomyocyte mitogen and matricellular protein POSTN (33, 34) in both the subtransplant and remote septal zones, thus further strengthening the cellular and molecular mechanisms behind the observed functional improvement after AAM patch transplantation.
The secreted matricellular protein POSTN mediates cell-matrix interactions and repair after tissue injury. As shown earlier, our data support the association of POSTN expression and myocardial regenerative signaling via the Rho-kinase pathway (23) . During tissue repair and healing after myocardial infarction, POSTN has been shown to be secreted to cardiac interstitium mainly by activated cardiac fibroblasts (23) . POSTN can stimulate cardiomyocyte re-entry to the cell cycle and prevent myocardial rupture after infarction (23, 33) . We demonstrated here that epicardial AAMs patch therapy resulted in myocardial salvage and functional restoration and was associated with increased periostin gene and protein expression in subtransplant and septal myocardium. We propose that the AAMs-patch-induced expression of POSTN taken together with enhanced neoangiogenesis and anti-inflammatory response promotes formation of a pro-reparative myocardial microenvironment.
In the subtransplant myocardium, AAM patch transplantation increased myocardial expression of proteins associated with muscle formation, vasculature development, and glutathione metabolism compared with those in infarcted myocardium treated with ECM patch without micrografts. DEPs were also negatively associated with cellular infiltration. In both subtransplant and septal myocardium, remote to the transplant site, we discovered increased expression of proteins associated with cardiomyocyte contraction (including MYH7, MYL1, MYL6, MYL12B, ACTA1, ACTN4, DES and CAMK2D). Interestingly, the expression of proteins involved in glutathione metabolism and antioxidant defense (GSTM2, GSTA4, GPX3) 31 was also significantly increased in the subtransplant and remote septal sites treated by AAM patch therapy compared with those treated by ECM patch therapy. The observed Gpx3 gene expression difference between AAM and ECM patch groups further strengthens this association of the AAMs mechanism of action via enhanced myocardial antioxidant defences.
In addition, we found a significant increase in cell viability and a significant decrease in cell death and apoptosis in the septal zone in AAM patch-treated hearts. This prosurvival action is a documented paracrine effect of cardiac stem/progenitor cell therapy (35) .
Some concerns have been raised about potential inflammation and foreign-body effects caused by the transplantation of xenogeneic material, but a systematic review advocates the safety of CorMatrix (ECM patch) in human cardiac surgery (36) . MI, cell damage, and necrotic death of cardiac cells initiate an intense inflammatory response. Although the main purpose of inflammation is the removal of cellular debris and nonfunctional cells, the immunomodulatory actions exerted by infiltrating cells may contribute to tissue repair (37, 38) . M1 versus M2 macrophages are attributed with differential roles in the modulation of the inflammatory response. M1 macrophages are associated with increased cardiomyocyte injury, whereas M2
and endogenous cardiac macrophages are associated with more rapid degradation of dead cells and a suppressed immunological response (39) (40) (41) . We detected a decreased inflammatory reaction in the subtransplant zone challenged with ischemia and near the AAMs. We also identified increased angiogenesis and a strong trend towards increased muscle cell differentiation in this same zone with AAM patch transplantation. Thus, our results indicate that AAM patch transplantation might be modulating the inflammatory response following MI in a way that promotes functional myocardial recovery. However, further targeted studies on the inflammation-modulating mechanisms of epicardial AAM patch transplantation are
warranted.
In addition to the function of transplanted atrial appendage micrografts, the ECM patch itself likely possesses cardioprotective effects. This assumption is supported by several observations. First, LVEF, one of the most widely used parameter to assess cardiac pump function in clinical settings, remained more than 10 percentage points higher in both the ECM and AAM patch-treated groups acutely at the one-week time point postoperatively (Figure 2A) , demonstrating the profunctional effect of ECM patch transplantation itself onto the ischemic myocardium. Second, the same phenomenon with other functional ECHO follow-up parameters such as circumferential strain and strain rate was detected ( Figure 2 ). However, the AAM patch-treated group showed a trend towards improved LVEF during the longer 8-week follow-up period when compared to the ECM patch group; we propose that this phenomenon is attributable to AAMs transplantation and is most probably transmitted through the previously identified and discussed molecular and cellular processes. Third, the transmurality index and ventricular wall thickness measures of the infarction scar site (Figure 3 ) showed significant improvements with ECM patch transplantation alone at the 8-week time point postoperatively.
Here, although the AAM patch group pinpointed still further enhancement in the functional parameters from the ECM patch group, the effect between ECM patch and MI group is quite notable. These findings underline the crucial role of the ECM patch transplantation itself.
As a supportive structure, an epicardial ECM patch can alter the biomechanics of the failing left ventricle in a beneficial manner. The total work done by the heart (W) during one cardiac cycle is the sum of pressure-volume work, kinetic energy and tension heat:
(1) = + increased myocardial injury after ischemia/reperfusion in TGM2 -/knockout mice (43) .
When evaluating the results of our study, it must be kept in mind that the samples were collected eight weeks after intervention opening the window for evaluation of true maintained therapeutic effect. This time-point, however, does not enable us to characterize the early events that take place during active inflammation or at the early phases of tissue destruction and fibrosis (44) . Further research, especially targeting the earlier times of myocardial remodeling, is thus warranted to gain more in-depth understanding of the dynamics of healing induced by AAM patch. Nevertheless, it is plausible to state that the AAM patch transplantation has the ability to alter the pathological post-MI healing-by-scar dynamics by activating critical repair processes such as angiogenesis, cardioprotective and cardiogenic pathways, thus prolonging the reparative/restorative window or inducing a secondary healing response (27) .
In conclusion, our results demonstrate that the epicardially transplanted AAMenclosing matrix patch significantly improves myocardial function after ischemic damage. The composite graft's therapeutic effect is mediated by a combination of mechanical support, via ventricular unloading, and an activation of myocardium-protecting pathways, cardioregenerative signaling, and angiogenesis. These results strengthen the therapeutic profile of epicardial AAM patch transplantation as a cost-effective, clinically feasible cellular adjuvant therapy for myocardial rescue and repair.
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Methods
A full-length description of the methods is available as an online-only data supplement (Detailed Materials and Methods) and Figure 1 illustrates the main parts of the study protocol and setting. Briefly, both atrial appendages were harvested and processed to AAMs from three male donor mice for each syngeneic transplant (42 mice in total). Forty age-matched male mice (homozygous 129X1/SvJ) were divided into the following groups: Sham-operated (Sham group, n=4); left anterior descending artery (LAD) ligation to induce MI (MI group, n=9); LAD ligation followed by epicardial transplantation of ECM patch without AAMs (ECM patch group, n=13); and LAD ligation followed by AAM patch, an ECM patch with AAMs, transplantation (AAM patch group, n=14). Cardiac function was evaluated weekly by echocardiography (ECHO), and after an 8-week follow-up, animals were sacrificed, and hearts collected for analyses.
Another set of mice was used to evaluate the mechanisms of AAMs. Male mice (strain 129X1/SvJ) were divided into three groups to receive either epicardial ECM (n=7) or AAM (n=7) patch therapy after MI or Sham control (n=4). As previously described, animals were sacrificed, and hearts were collected and cryopreserved for samples after the 8-week followup. Transplant, subtransplant and remote septal tissue samples were dissected from cryosections and were subsequently processed for label free site-targeted proteomic analysis (DIA-nanoLC-HD-MS E ; AAM patch, n=4x3; ECM patch, n=4x3).
Statistics.
The statistical significance of column data presented in figures 2 to 5 was analysed using two-tailed Mann-Whitney U-test. Mann-Whitney U-test was chosen because the data was not normally distributed. The data normality was tested using Shapiro-Wilk test.
Data derived from the ECHO follow up was analysed using ordinary one-way ANOVA. 
